

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 July 2020 (09.07.2020)



(10) International Publication Number
WO 2020/141212 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) A61P 35/00 (2006.01)

C07K 16/00 (2006.01)

(21) International Application Number:

PCT/EP2020/050072

(22) International Filing Date:

03 January 2020 (03.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19150349.9 04 January 2019 (04.01.2019) EP

19163486.4 18 March 2019 (18.03.2019) EP

(71) Applicant: **ETHERNA IMMUNOTHERAPIES NV**
[BE/BE]; Galileilaan 19, 2845 Niel (BE).

(72) Inventors: **DE KOKER, Stefaan**; eTheRNA Immunotherapies NV, Galileilaan 19, 2845 Niel (BE). **BIALKOWSKI, Lukasz**; eTheRNA Immunotherapies NV, Galileilaan 19, 2845 Niel (BE).

(74) Agent: **LC PATENTS**; Kempische Steenweg 542A, 3500 Hasselt (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MRNA VACCINE

Fig. 2



(57) Abstract: The present invention in general relates to a combination of mRNA molecules encoding functional immunostimulatory proteins and a PD-1 pathway inhibitor. In particular, it relates to a combination of one or more mRNA molecules encoding at least one functional immunostimulatory protein selected from the list comprising: CD40L, CD70 and cTLR4; and a PD-1 pathway inhibitor, optionally also in the form of an mRNA molecule. The present invention further relates to vaccines comprising such combination, as well as uses of the combinations and vaccine of the present invention in human or veterinary medicine, in particular in the prevention and/or treatment of cell proliferative disorders.

WO 2020/141212 A1